Gout, a painful form of inflammatory arthritis, is set to become far more common in the coming decades. Projections indicate that global cases will rise significantly over the next 25 years, driven by aging populations, obesity, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with the disease, and an even larger group—44 million people—have uric acid levels above the normal range, putting them at risk. This looming public health challenge underscores the urgent need for better treatment options, as existing therapies often come with debilitating side effects that lead patients to stop taking them.
Current standard-of-care treatments, primarily oral xanthine oxidase inhibitors (XOIs), can cause severe gastrointestinal issues, kidney toxicity, and cardiovascular risks, especially with long-term or high-dose use. Moreover, some treatments initially trigger more gout flare-ups, further discouraging adherence. Approximately 3% to 5% of patients cannot tolerate XOIs at all, and these drugs carry boxed warnings for cardiovascular risk. This leaves a significant unmet need for a safer, more effective therapy.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, believes it has a solution. The company has developed XORLO™, a proprietary formulation of oxypurinol that utilizes a liposomal delivery system to overcome the historically poor oral absorption of the drug. According to XORTX, this approach enables high bioavailability and rapid absorption, allowing for effective uric acid reduction at substantially lower total daily doses. By minimizing toxic-level exposure and severe gastrointestinal side effects associated with high-dose traditional therapies, XORLO could offer a better-tolerated alternative.
The company is making tangible progress toward bringing XORLO to market. It recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This study is based on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol drug substance has already begun, and XORTX is working with its manufacturing partner to produce commercial drug batches. The two-part trial will characterize the pharmacokinetics and efficacy of XORLO, with the goal of supporting a marketing application.
Regulatory milestones are also in sight. XORTX is working toward a new drug application submission to the FDA, with a new Investigational New Drug (IND) application prepared for submission in the fourth quarter of 2026. If the clinical trial is successful, the company intends to request a pre-NDA meeting and prepare an NDA submission while engaging in pre-commercialization activities. XORTX is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
"Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program," said Allen Davidoff, Co-CEO of XORTX. "It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option."
For patients and investors alike, XORTX's progress represents a potential breakthrough in gout management. If approved, XORLO could address the adherence challenges that plague current therapies, improving quality of life for millions. The company's efforts are closely watched, as detailed in a report published on Benzinga, and further disclosures are available here. The original release can be viewed on www.newmediawire.com.
